Platelet Aggregation and Its Association With Stent Thrombosis and Bleeding in Clopidogrel-Treated Patients
Open accessThe claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Multiplate results correlate well with bleeding and thromboembolic complications in patients undergoing coronary stenting and cardiac surgery.
“Of note, Multiplate results have been shown to bear a good correlation to bleeding and thromboembolic complications in patients undergoing coronary stenting and cardiac surgery.44,45”
From Point-of-Care Testing: A Prospective, Randomized Clinical Trial of Efficacy in Coagulopathic Cardiac Surgery Patients (2012) · cites this paper as [45]
In “Initial Evidence of a Therapeutic Window” (page not available), Multiplate-measured platelet aggregation is associated with stent thrombosis and major bleeding among clopidogrel-treated patients undergoing coronary stenting. The paper does not report findings for patients undergoing cardiac surgery, so it supports only the coronary-stenting part of the cited sentence. (LLM, conf=0.88)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
No references could be resolved yet.
Research works printed but not linked: 5
- Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Variability in individual responsiveness to clopidogrel: clinical implications, manage- ment, and future perspectives. J Am Coll Cardiol 2007;49:1505-16.
- Sibbing D, Schulz S, Braun S, et al. Antiplatelet effects of clopidogrel and bleeding in patients undergoing coronary stent placement. J Thromb Haemost 2010;8:250 -6.
- Doyle BJ, Rihal CS, Gastineau DA, Holmes DR Jr. Bleeding, blood transfusion, and increased mortality after percutaneous coronary inter- vention: implications for contemporary practice. J Am Coll Cardiol 2009;53:2019 -27.
- Azar AJ, Cannegieter SC, Deckers JW, et al. Optimal intensity of oral anticoagulant therapy after myocardial infarction. J Am Coll Cardiol 1996;27:1349 -55.
- Sibbing D, Braun S, Morath T, et al. Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. J Am Coll Cardiol 2009;53:849 -56.
Cited by
Sorted by citations
Management of severe perioperative bleeding
Kozek‐Langenecker, S. A., Afshari, A., Albaladejo, P., Aldecoa, C., ROBERTIS, E. D., Filipescu, D. C., Fries, D. R., Görlinger, K., Haas, T., Imberger, G. L., et al. (2013) · European Journal of Anaesthesiology · doi:10.1097/eja.0b013e32835f4d5b · Cited by 900 · see citing works
Stone, G. W., Witzenbichler, B., Weisz, G., Rinaldi, M. J., Neumann, F., Metzger, D. C., Henry, T. D., Cox, D. A., Duffy, P. L., Mazzaferri, E. L., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)61170-8 · Cited by 858 · see citing works
Weber, C. F., Görlinger, K., Meininger, D., Herrmann, E., Bingold, T., Moritz, A., Cohn, L. H., & Zacharowski, K. (2012) · Anesthesiology · doi:10.1097/aln.0b013e318264c644 · Cited by 625 · see citing works
Sibbing, D., Aradi, D., Alexopoulos, D. K., ten Berg, J. M., Bhatt, D. L., Bonello, L., Collet, J., Cuisset, T., Franchi, F., Groß, L., et al. (2019) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2019.03.034 · Cited by 542 · see citing works
“For more than a decade after the first description of clopidogrel’s wide response variability in 2003 (4), numerous observational studies have provided data in support of P2Y12-directed PFT for cardiovascular risk prediction after elective PCI (10,11,21,38,42).”
BackgroundResultInfluentialSelf-citationAradi, D., Kirtane, A. J., Bonello, L., Gurbel, P. A., Tantry, U. S., Huber, K., Freynhofer, M. K., ten Berg, J. M., Janssen, P. W. A., Angiolillo, D. J., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv104 · Cited by 372 · see citing works
Self-citationCampo, G., Parrinello, G., Ferraresi, P., Lunghi, B., Tebaldi, M., Miccoli, M., Marchesini, J., Bernardi, F., Ferrari, R., & Valgimigli, M. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.12.047 · Cited by 351 · see citing works
Aradi, D., Storey, R. F., Komócsi, A., Trenk, D., Gulba, D. C., Kiss, R. G., Husted, S., Bonello, L., Sibbing, D., Collet, J., et al. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht375 · Cited by 275 · see citing works
“Together with the predictive value of HPR in predicting thrombotic complications, the higher risk forbleeding in patients with LPRsuggests the relevance of a therapeutic window for P2Y12-receptor inhibitors, in that both thrombotic and bleeding complications might be the lowest.(75,78,79) Therefore, the approach of us…”
BackgroundSelf-citationSarafoff, N., Martischnig, A., Wealer, J., Mayer, K., Mehilli, J., Sibbing, D., & Kastrati, A. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.02.036 · Cited by 236 · see citing works
Self-citationBonello, L., Pansiéri, M., Mancini, J., Bonello, R., Maillard, L., Barnay, P., Rossi, P., Mokhtar, O. A., Jouve, B., Collet, F., et al. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.04.017 · Cited by 209 · see citing works
Sibbing, D., Koch, W., Maßberg, S., Byrne, R. A., Mehilli, J., Schulz, S., Mayer, K., Bernlochner, I., Schömig, A., & Kastrati, A. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr155 · Cited by 186 · see citing works
Self-citationAngiolillo, D., Schneider, D., Bhatt, D. L., French, W., Price, M., Saucedo, J., Shaburishvili, T., Huber, K., Prats, J., Liu, T., et al. (2012) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-012-0737-3 · Cited by 162 · see citing works
Response Variability to P2Y12 Receptor Inhibitors
Siller-Matula, J. M., Trenk, D., Schrör, K., Gawaz, M., Kristensen, S. D., Storey, R. F., & Huber, K. (2013) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2013.06.011 · Cited by 148 · see citing works
“(39,40) MEA:ADP 2,533 PCI In-hospital TIMI major bleeding 3.”
MethodManagement of hemorrhage in cardiothoracic surgery.
Görlinger, K., Shore-lesserson, L., Dirkmann, D., Hanke, A., Rahe-Meyer, N., & Tanaka, K. A. (2013) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2013.05.014 · Cited by 145 · see citing works
“interventional and perioperative bleeding in a timely manner and also to avoid thromboembolic events at the same time.(41,71,73,82,83) Therefore, whole-blood impedance aggregometry ideally complements thromboelastometry in perioperative POC diagnostics, particularly in cardiothoracic surgery.”
Angiolillo, D. J., Galli, M., Alexopoulos, D. K., Aradi, D., Bhatt, D. L., Bonello, L., Capodanno, D., Cavallari, L. H., Collet, J., Cuisset, T., et al. (2024) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2024.08.027 · Cited by 130 · see citing works
Self-citationBonello, L., Mancini, J., Pansiéri, M., Maillard, L., ROSSI, P., Collet, F., Jouve, B., Wittenberg, O., Laine, M., Michelet, P., et al. (2012) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2012.04875.x · Cited by 127 · see citing works
Personalized antiplatelet treatment after percutaneous coronary intervention: The MADONNA study
Siller-Matula, J. M., Francesconi, M., Dechant, C., Jilma, B., Maurer, G., Delle‐Karth, G., Gouya, G., Ruzicka, K., Podczeck-Schweighofer, A., & Christ, G. (2012) · International Journal of Cardiology · doi:10.1016/j.ijcard.2012.05.040 · Cited by 114 · see citing works
“We used an impedance aggregometry in whole blood (MEA), which is a point of care platelet function test with a good prognostic value for thrombotic and bleeding adverse events after coronary stenting [9,11,41–44].”
MethodPatti, G., Pasceri, V., Vizzi, V., Ricottini, E., & Sciascio, G. D. (2011) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2010.11.025 · Cited by 116 · see citing works
Bhatt, D. L., Paré, G., Eikelboom, J. W., Simonsen, K. L., Emison, E., Fox, K. A. A., Steg, P. G., Montalescot, G., Bhakta, N., Hacke, W., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs059 · Cited by 97 · see citing works
“sponse, nor between measured anti-platelet response and anti-thrombotic efficacy or bleeding propensity.(19,20) Additionally, CYP2C19 is not the only pathway involved with clopidogrel activa-”
BackgroundSelf-citationSchulz, S., Richardt, G., Laugwitz, K., Morath, T., Neudecker, J., Hoppmann, P., Mehran, R., Gershlick, A., Tölg, R., Fiedler, K. A., et al. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu182 · Cited by 108 · see citing works
Self-citationThe Evolution of Antiplatelet Therapy in the Treatment of Acute Coronary Syndromes
Angiolillo, D. (2012) · Drugs · doi:10.2165/11640880-000000000-00000 · Cited by 105 · see citing works
Mangiacapra, F., Patti, G., Barbato, E., Peace, A., Ricottini, E., Vizzi, V., Gatto, L., D'Ambrosio, A., de Bruyne, B., Wijns, W., et al. (2012) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2012.01.009 · Cited by 100 · see citing works
Potential value of transfusion protocols in cardiac surgery
Görlinger, K., Dirkmann, D., & Hanke, A. (2013) · Current Opinion in Anaesthesiology · doi:10.1097/aco.0b013e32835ddca6 · Cited by 93 · see citing works
“This may allow for adjusting platelet function to a therapeutic window in order to stop bleeding on time but to avoid thromboembolic events at the same time [32,57,58].”
BackgroundGorog, D. A., Ferreiro, J. L., Ahrens, I., Ako, J., Geisler, T., Halvorsen, S., Huber, K., Jeong, Y., Navarese, E. P., Rubboli, A., et al. (2023) · Nature Reviews Cardiology · doi:10.1038/s41569-023-00901-2 · Cited by 98 · see citing works
“However, the wide interindividual pharmacodynamic response to clopidogrel is associated with variation in individual bleeding risk, such that patients with greater P2Y 12 inhibition have higher rates of bleeding 31,32 .”
BackgroundSelf-citationPlatelet function tests in clinical cardiology: unfulfilled expectations.
Gorog, D. A., & Fuster, V. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.11.080 · Cited by 83 · see citing works
“Analyses of cutoff values derived from eceiver-operating characteristic curves revealed the exisence of a “therapeutic window” for P2Y12 receptor inhibiion, within which sufficient antiplatelet effect could be chieved without increased bleeding (94).”
BackgroundCoagulation management in patients undergoing mechanical circulatory support
Görlinger, K., Bergmann, L., & Dirkmann, D. (2012) · Best practice & research. Clinical anaesthesiology · doi:10.1016/j.bpa.2012.04.003 · Cited by 80 · see citing works
Cao, D., Chandiramani, R., Chiarito, M., Claessen, B. E. P. M., & Mehran, R. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa824 · Cited by 98 · see citing works
Hazarbasanov, D., Velchev, V., Finkov, B., Postadzhiyan, A., Kostov, E., Rifai, N., & Aradi, D. (2012) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-012-0684-z · Cited by 69 · see citing works
Switching acute coronary syndrome patients from prasugrel to clopidogrel.
Kerneis, M., Silvain, J., Abtan, J., Cayla, G., O'Connor, S., Barthélémy, O., Vignalou, J., Beygui, F., Brugier, D., Martin, R., et al. (2013) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2012.09.012 · Cited by 68 · see citing works
Cattaneo, M. (2012) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2011.04602.x · Cited by 68 · see citing works
Pre-treatment with P2Y 12 inhibitors in ACS patients: who, when, why, and which agent?
Sibbing, D., Kastrati, A., & Berger, P. B. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv717 · Cited by 67 · see citing works
“In line with the belief that platelets are key mediators of both ischaemic coronary events and primary haemostasis, it has been shown that the level of platelet inhibition achieved at the time of the intervention (PCI) correlates with both thrombotic and bleeding events.(10) Moreover, some patients undergoing coronary…”
BackgroundSelf-citationHarrison, P., & Lordkipanidzé, M. (2013) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2013.03.003 · Cited by 70 · see citing works
Würtz, M., & Grove, E. L. (2012) · Current Pharmaceutical Design · doi:10.2174/138161212803251925 · Cited by 64 · see citing works
“It has recently been suggested that a similar index is relevant for the assessment of how patients respond to clopidogrel [301].”
BackgroundHigh platelet reactivity and clinical outcome – Fact and fiction
Sibbing, D., Byrne, R. A., Bernlochner, I., & Kastrati, A. (2011) · Thrombosis and Haemostasis · doi:10.1160/th11-01-0040 · Cited by 67 · see citing works
“Notwithstanding, it seems unlikely that all patients will benefit from more potent antiplatelet drugs as the value of antithrombotic treatment is determined by the balance between the prevention of ischaemic complications and the induction of bleeding (9, 10); the latter is – not surprisingly – a major shortcoming of…”
BackgroundSelf-citationNakamura, M., Isshiki, T., Kimura, T., Ogawa, H., Yokoi, H., Nanto, S., Takayama, M., Kitagawa, K., Ikeda, Y., & Saito, S. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.01.026 · Cited by 57 · see citing works
Cytochrome P450 pharmacogenetics in African populations
Alessandrini, M., Asfaha, S. M., Dodgen, T. M., Warnich, L., & Pepper, M. S. (2013) · Drug Metabolism Reviews · doi:10.3109/03602532.2013.783062 · Cited by 67 · see citing works
“It catalyzes the metabolism of xenobiotics and several therapeutic drugs, such as bupropion, cyclophosphamide, efavirenz and nevirapine (Phillips & Mallal, 2008; Sibbing et al., 2010b; Telenti & Zanger, 2008).”
BackgroundKrishna, V., Diamond, G., & Kaul, S. (2012) · Circulation · doi:10.1161/circulationaha.111.075242 · Cited by 56 · see citing works
Rotational Thromboelastometry (ROTEM®)
Görlinger, K., Dirkmann, D., & Hanke, A. (2016) · Springer eBooks · doi:10.1007/978-3-319-28308-1_18 · Cited by 45 · see citing works
Siller-Matula, J., Trenk, D., Schrör, K., Gawaz, M., Kristensen, S., Storey, R., & Huber, K. (2015) · Thrombosis and Haemostasis · doi:10.1160/th14-13-0238 · Cited by 51
High on-treatment platelet reactivity – definition and measurement
Cattaneo, M. (2013) · Thrombosis and Haemostasis · doi:10.1160/th12-10-0758 · Cited by 50
“According to some studies, the technique is able not only to identify patients at risk of MACE, but also those at risk of bleeding (16-19).”
ResultAdvocating cardiovascular precision medicine with P2Y12 receptor inhibitors
Winter, M., Grove, E. L., Caterina, R. D., Gorog, D. A., Ahrens, I., Geisler, T., Gurbel, P. A., Tantry, U. S., Navarese, E. P., & Siller-Matula, J. M. (2017) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvw044 · Cited by 50 · see citing works
“74, sensitivity: 72–77%, and specificity: 62–66%.(29,30,121,122) The VerifyNow P2Y12 assay (Accumetrics, San Diego, CA, USA) has a higher reproducibility compared with other platelet Figure 3 The relationship between the CYP2C19 metabolizer status and the response to different clopidogrel loading doses.”
BackgroundDeuterated Clopidogrel Analogues as a New Generation of Antiplatelet Agents
Zhu, Y., Zhou, J., & Jiao, B. (2013) · ACS Medicinal Chemistry Letters · doi:10.1021/ml300460t · Cited by 78 · see citing works
How I use laboratory monitoring of antiplatelet therapy
Michelson, A. D., & Bhatt, D. L. (2017) · Blood · doi:10.1182/blood-2017-03-742338 · Cited by 51 · see citing works
Personalized antiplatelet therapy with P2Y 12 receptor inhibitors: benefits and pitfalls
Winter, M., Koziński, M., Kubica, J., Aradi, D., & Siller-Matula, J. M. (2015) · Advances in Interventional Cardiology · doi:10.5114/pwki.2015.55596 · Cited by 52 · see citing works
“74; sensitivity: 72–77% and specificity: 62–66%) [64, 65, 128, 129].”
Prasugrel monitoring and bleeding in real world patients.
Cayla, G., Cuisset, T., Silvain, J., O'Connor, S., Kerneis, M., Castelli, C., Quilici, J., Bonnet, J., Alessi, M., Morange, P., et al. (2013) · American Journal of Cardiology · doi:10.1016/j.amjcard.2012.08.043 · Cited by 43
Johnston, L., Larsen, P., Flamme, A. L. L., & Harding, S. (2013) · Platelets · doi:10.3109/09537104.2012.694086 · Cited by 42
Jaitner, J., Stegherr, J., Morath, T., Braun, S., Bernlochner, I., Schömig, A., Kastrati, A., & Dirk, S. (2010) · Thrombosis and Haemostasis · doi:10.1160/th10-07-0440 · Cited by 42
“In relation to this, for the most commonly used assays of platelet function testing, a cut-off approach is favoured for both HPR phenotyping and risk prediction (18, 28).”
MethodSelf-citationPlatelet Function Testing in Patients on Antiplatelet Medications
Gross, L., Aradi, D., & Sibbing, D. (2016) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0035-1570083 · Cited by 41
Self-citationSchüpke, S., Bernlochner, I., Morath, T., Braun, S., Hausleiter, J., Massberg, S., Schunkert, H., Laugwitz, K.-L., Kastrati, A., Sibbing, D., et al. (2014) · Thrombosis and Haemostasis · doi:10.1160/th13-10-0874 · Cited by 45 · see citing works
“Details of this study including inclusion and exclusion criteria have been reported previously (11).”
BackgroundSelf-citationKirtane, A. J., Parikh, P. B., Stuckey, T., Xu, K., Witzenbichler, B., Weisz, G., Rinaldi, M. J., Neumann, F., Metzger, D. C., Henry, T. D., et al. (2015) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2015.08.032 · Cited by 36 · see citing works
Siller-Matula, J. M., Gruber, C., Francesconi, M., Dechant, C., Jilma, B., Delle‐Karth, G., Grohs, K., Podczeck-Schweighofer, A., & Christ, G. (2014) · Clinical Science · doi:10.1042/cs20140310 · Cited by 42 · see citing works
Platelet Function Testing in Contemporary Clinical and Interventional Practice
Franchi, F., Rollini, F., Cho, J. R., Ferrante, E., & Angiolillo, D. J. (2014) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-014-0300-y · Cited by 40 · see citing works
Platelet function testing in atherothrombotic disease.
Grove, E., Storey, R., & Würtz, M. (2012) · Current pharmaceutical design · doi:10.2174/138161212803251862 · Cited by 39
“In conclusion, they argue in favour of a so-called “sweet-spot”; a therapeutic window ranging from 189 to 467 aggregation units x minute in which patients are at a reduced risk of both thrombotic (stent thrombosis) and haemorrhagic events [107].”
BackgroundPlatelet Function Testing and Tailored Antiplatelet Therapy
Janssen, P. W. A., & ten Berg, J. M. (2013) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-013-9458-z · Cited by 38 · see citing works
Platelet function testing and prediction of procedural bleeding risk
Grove, E., Hossain, R., & Storey, R. (2013) · Thrombosis and Haemostasis · doi:10.1160/th12-11-0806 · Cited by 37 · see citing works
“These findings, combined with observed increased risk of stent thrombosis in those with a poor response to clopidogrel, led to the proposal that a therapeutic window of P2Y12 inhibition exists in patients undergoing PCI (53).”
BackgroundStratified Approaches to Antiplatelet Therapies Based on Platelet Reactivity Testing
Ostrowska, M., Kubica, J., Adamski, P., Kubica, A., Eyileten, C., Postula, M. A., Toma, A., Hengstenberg, C., & Siller-Matula, J. M. (2019) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2019.00176 · Cited by 40 · see citing works
Platelet Function and Genetic Testing
Angiolillo, D. J., Ferreiro, J. L., Price, M. J., Kirtane, A. J., & Stone, G. W. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.08.704 · Cited by 32 · see citing works
Thienopyridines and Other ADP-Receptor Antagonists
Bernlochner, I., & Sibbing, D. (2012) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-29423-5_7 · Cited by 29 · see citing works
Self-citationLangwieser, N., Bernlochner, I., Wustrow, I., Dirschinger, R., Jaitner, J., Dommasch, M., Bradaric, C., Laugwitz, K., & Ibrahim, T. (2016) · Phlebology · doi:10.1177/0268355515596289 · Cited by 31
“Patients with enhanced response to clopidogrel, defined as PA< 188 AU min, were switched to clopidogrel 75mg every second day.(18) Patients were Langwieser et al.”
MethodOrban, M., Mayer, K., Morath, T., Bernlochner, I., Hadamitzky, M., Braun, S., Schulz, S., Hoppmann, P., Hausleiter, J., Tiroch, K., et al. (2014) · Thrombosis and Haemostasis · doi:10.1160/th14-06-0489 · Cited by 30
“Low platelet reactivity (LPR, ≤ 188 AU x min) was also defined according to prior studies (18, 19).”
MethodSelf-citationAradi, D., Kuliczkowski, W., Atar, D., & Serebruany, V. (2011) · Thrombosis and Haemostasis · doi:10.1160/th11-09-0622 · Cited by 28
“Although less well established, the Multiplate device had a receiver-operating curve (ROC)-defined cut-off for bleeding that was used as a limit for low platelet reactivity (LPR): <18U (11).”
MethodBF061, a novel antiplatelet and antithrombotic agent targeting P2Y12 receptor and phosphodiesterase
Hu, L., Fan, Z.-C., Du, H., Ni, R., Zhang, S., Yin, K., Ye, J.-Q., Zhang, Y., Wei, X.-B., Zhang, X., et al. (2011) · Thrombosis and Haemostasis · doi:10.1160/th11-06-0400 · Cited by 28
Sarafoff, N., Neumann, L., Morath, T., Bernlochner, I., Mehilli, J., Schömig, A., Kastrati, A., & Sibbing, D. (2011) · American Heart Journal · doi:10.1016/j.ahj.2010.11.010 · Cited by 28
Self-citationDias, J. D., Pottgießer, T., Hartmann, J., Duerschmied, D., Bode, C., & Achneck, H. E. (2019) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-019-01971-1 · Cited by 27 · see citing works
Predictors of antiplatelet response to prasugrel during maintenance treatment
Mayer, K., Orban, M., Bernlochner, I., Braun, S., Schulz, S., Gross, L., Hadamitzky, M., Schunkert, H., Laugwitz, K., Massberg, S., et al. (2015) · Platelets · doi:10.3109/09537104.2013.863857 · Cited by 27
“AU min) were also defined according to prior studies [13, 18].”
ResultSelf-citationLee, J. H., Ahn, S. G., Park, B., Park, S. W., Kang, Y. S., Lee, J., Youn, Y. J., Ahn, M., Kim, J., Yoo, B., et al. (2015) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2015.30.5.620 · Cited by 26 · see citing works
Assessment of oral antithrombotic therapy by platelet function testing
Tantry, U. S., & Gurbel, P. A. (2011) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2011.107 · Cited by 24 · see citing works
Steblovnik, K., Blinc, A., Mijovski, M. B., Kranjec, I., Melkić, E., & Noč, M. (2015) · EuroIntervention · doi:10.4244/eijy14m05_02 · Cited by 27 · see citing works
Straub, N., Beivers, A., Lenk, E., Aradi, D., & Sibbing, D. (2013) · Thrombosis and Haemostasis · doi:10.1160/th13-08-0679 · Cited by 28 · see citing works
Self-citationAdvances in the monitoring of anti-P2Y12 therapy
Harrison, P. J. (2012) · Platelets · doi:10.3109/09537104.2012.704650 · Cited by 22 · see citing works
“[10] have also provided preliminary evidence of a therapeutic window using MEA to identify patients with either stent thrombosis or bleeding.”
BackgroundInfluentialKoul, S., Andell, P., Martinsson, A., Smith, J. G., Scherstén, F., Harnek, J., Götberg, M., Norström, E., Björnsson, S., & Erlinge, D. (2014) · BMC Cardiovascular Disorders · doi:10.1186/1471-2261-14-189 · Cited by 21
“Furthermore there is also an immediate increased risk of bleeding [4].”
BackgroundBreet, N., van Donkersgoed, H., van Werkum, J. V., Bouman, H., Kelder, J., Zijlstra, F., Hackeng, C., & ten Berg, J. T. (2011) · Netherlands Heart Journal · doi:10.1007/s12471-011-0105-5 · Cited by 21
Schulz, S., Richardt, G., Laugwitz, K., Mehran, R., Gershlick, A., Morath, T., Mayer, K., Neudecker, J., Tölg, R., Ibrahim, T., et al. (2014) · Clinical Cardiology · doi:10.1002/clc.22268 · Cited by 20
Self-citationCurrent evidence for genetic testing in clopidogrel-treated patients undergoing coronary stenting.
Sibbing, D., Bernlochner, I., Kastrati, A., Paré, G., & Eikelboom, J. (2011) · Circulation. Cardiovascular Interventions · doi:10.1161/circinterventions.111.962183 · Cited by 20
Self-citationClopidogrel: A Pharmacogenomic Perspective on its Use in Coronary Artery Disease
Terpening, C. M. (2010) · Clinical Medicine Insights: Cardiology · doi:10.4137/cmc.s4323 · Cited by 20 · see citing works
Peri-Procedural Platelet Reactivity in Percutaneous Coronary Intervention
Alexopoulos, D. K., Xenogiannis, I., Vlachakis, P. K., Tantry, U. S., & Gurbel, P. A. (2018) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1649484 · Cited by 19 · see citing works
“1,46,47 Notably, in a recent study involving patients after PCI on aspirin and clopidogrel, reticulated platelet fraction — an index of increased platelet turnover — but not platelet function, was predictive of 6-month major adverse cardiovascular event (MACE).”
Mazzeffi, M. A., Lee, K., Taylor, B. S., & Tanaka, K. A. (2017) · Korean Journal of Anesthesiology · doi:10.4097/kjae.2017.70.4.379 · Cited by 23 · see citing works
“Conversely, extremely decreased (low on-treatment) platelet activity upon testing may be regarded as an increased risk for bleeding complications [9,10], therefore dosing of the respective agents needs to be carefully adjusted in patients at high risk for bleeding.”
BackgroundLaine, M., Gaubert, M., Frère, C., Peyrol, M., Thuny, F., Yvorra, S., Chelini, V., Bultez, B., Luigi, S., Mokrani, Z., et al. (2015) · Platelets · doi:10.3109/09537104.2014.959914 · Cited by 18 · see citing works
“Consistently, a strong relationship between PR following P2Y12 antagonists loading dose (LD) and both thrombotic and bleeding events in patients undergoing PCI was demonstrated supporting PR as a surrogate end-point [3, 4].”
BackgroundInfluentialDirect oral anticoagulants and antiplatelet agents
Spannagl, M., & Sibbing, D. (2013) · Hämostaseologie · doi:10.5482/hamo-13-11-0055 · Cited by 17 · see citing works
Self-citationBernlochner, I., Mayer, K., Morath, T., Orban, M., Schulz, S., Schömig, A., Braun, S., Kastrati, A., & Sibbing, D. (2013) · Thrombosis and Haemostasis · doi:10.1160/th12-08-0552 · Cited by 13 · see citing works
“Low platelet reactivity (LPR, ≤188 AU x min) and normal platelet reactivity (NPR, 189-467 AU x min) were also defined on the basis of prior studies (19, 20).”
BackgroundMethodSelf-citationPark, Y., Jeong, Y., Kim, I.-S., Yun, S.-E., Kwon, T., Hwang, S., Kwak, C., & Hwang, J. (2012) · Platelets · doi:10.3109/09537104.2011.614974 · Cited by 17
“identified threshold of MEA (ADPtest 19 U) by a large registry clinical outcome data (n1⁄4 2533) [21].”
MethodPredictors of high on-clopidogrel platelet reactivity in patients with acute coronary syndrome
Leé, S., Hizoh, I., Kovács, A., Horváth, Z., Kiss, N., Tóth-Zsámboki, E., & Kiss, R. (2016) · Platelets · doi:10.3109/09537104.2015.1054799 · Cited by 16
The use of platelet function testing in PCI and CABG patients
Janssen, P. W. A., ten Berg, J. M., & Hackeng, C. M. (2014) · Blood Reviews · doi:10.1016/j.blre.2014.03.004 · Cited by 18 · see citing works
“1) [60,75,84,91].”
Whole Blood Assay: Thromboelastometry
Görlinger, K., Iqbal, J., Dirkmann, D., & Tanaka, K. A. (2016) · Springer eBooks · doi:10.1007/978-3-319-30726-8_5 · Cited by 16 · see citing works
Low Response to Clopidogrel in Coronary Artery Disease.
Bobescu, E., Covaciu, A., Rus, H., Rogozea, L., Badea, M., & Marceanu, L. (2020) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001099 · Cited by 15 · see citing works
Bernlochner, I., Mayer, K., Orban, M., Morath, T., Jaitner, J., Rössner, L., Gross, L., Laugwitz, K., Kastrati, A., & Sibbing, D. (2016) · Platelets · doi:10.1080/09537104.2016.1190007 · Cited by 15
“The rate of HTPR on prasugrel and ticagrelor (≥468 AU × min corresponding to >46 AU) and the rate of enhanced platelet reactivity (≤188 AU × min corresponding to <19 AU) [18, 25] as well as PR at 2 weeks after randomization were secondary end points.”
BackgroundSelf-citationPain-associated respiratory failure in chest trauma.
Ahn, Y., Görlinger, K., Alam, H., & Eikermann, M. (2013) · Anesthesiology · doi:10.1097/aln.0b013e318283996b · Cited by 15
Kim, I.-S., Jeong, Y., Park, Y., Yoon, S.-E., Kwon, T., Park, J.-R., Hwang, S., Koh, E.-H., Kwak, C., Hwang, J., et al. (2012) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2011.04131.x · Cited by 15
Clinical Tests of Platelet Function
Harrison, P., & Lordkipanidzé, M. (2012) · Elsevier eBooks · doi:10.1016/b978-0-12-387837-3.00026-2 · Cited by 24 · see citing works
Oral antiplatelet therapy: impact for transfusion medicine
Gremmel, T., & Panzer, S. (2017) · Vox Sanguinis · doi:10.1111/vox.12537 · Cited by 14
Practical Aspects of Monitoring of Antiplatelet Therapy
Jovanovic, L., Antonijević, N., Novaković, T., Savić, N., Terzić, B., Živković, I., Radovanović, N., & Ašanin, M. (2016) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0036-1586230 · Cited by 14
Bonello, L., Laine, M., Baumstarck, K., Fernandez, J., Maillard, L., Peyrol, M., Bessereau, J., Aradi, D., Camilleri, É., Roubille, F., et al. (2013) · International Journal of Cardiology · doi:10.1016/j.ijcard.2013.07.147 · Cited by 14
Suboptimal response to clopidogrel and the effect of prasugrel in acute coronary syndromes.
Johnston, L., Larsen, P., Flamme, A. L. L., Michel, J., Simmonds, M., & Harding, S. (2013) · International Journal of Cardiology · doi:10.1016/j.ijcard.2012.03.080 · Cited by 14 · see citing works
Bernlochner, I., Morath, T., Brown, P. B., Zhou, C.-M., Baker, B. A., Gupta, N., Jakubowski, J., Winters, K., Schömig, A., Kastrati, A., et al. (2013) · Platelets · doi:10.3109/09537104.2011.654003 · Cited by 14
Self-citationAntiplatelet drug therapy: role of pharmacodynamic and genetic testing.
Tello-Montoliu, A., Ueno, M., & Angiolillo, D. (2011) · Future Cardiology · doi:10.2217/fca.11.14 · Cited by 14 · see citing works
“Recent investigations have identified this therapeutic window in patients undergoing elective PCI using the Multiplate and VerifyNow assays, but warrant c onfirmation in larger datasets (Figure 3) [31,32].”
MethodKafian, S., Mobarrez, F., Kalani, M., Wallén, H., & Samad, B. A. (2011) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.3109/00365513.2011.604731 · Cited by 13 · see citing works
“Numerically we fi nd that a quarter of the patients have insuffi cient platelet inhibition towards ADP and this fi gure is slightly higher than that reported by Sibbing, who found that only 17% were low responders [8].”
BackgroundResultInfluentialThe Current Role of Platelet Function Testing in Clinical Practice
Mason, G., & Rabbolini, D. J. (2021) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0041-1728786 · Cited by 16 · see citing works
Stratz, C., Nührenberg, T. G., Valina, C. M., Löffelhardt, N., Mashayekhi, K., Ferenc, M., Trenk, D., Neumann, F., & Hochholzer, W. (2018) · Thrombosis and Haemostasis · doi:10.1160/th17-07-0466 · Cited by 17 · see citing works
Woźniak, S., Woźniak, K., Hryniewiecki, T., Kruk, M., Różański, J., & Kuśmierczyk, M. (2016) · Kardiochirurgia i torakochirurgia polska = Polish journal of cardio-thoracic surgery · doi:10.5114/kitp.2016.58957 · Cited by 12 · see citing works
“Dual antiplatelet therapy, however, significantly increases the risk of postoperative bleeding [4].”
BackgroundUrban, P. M., Valdés, M., Menown, I. B. A., Eberli, F. R., Alhaddad, I. A., Hildick‐Smith, D., Iosseliani, D. G., Roffi, M., Oldroyd, K. G., Kalloudi, E., et al. (2015) · Catheterization and Cardiovascular Interventions · doi:10.1002/ccd.25892 · Cited by 14 · see citing works
Aradi, D., Sibbing, D., & Bonello, L. (2013) · International Journal of Cardiology · doi:10.1016/j.ijcard.2012.12.026 · Cited by 12
“These analyses provide initial evidence for the existence of a therapeutic window with P2Y12-receptor inhibition [18,19,21], within that both thrombotic and bleeding events are the lowest; an attitude that is widely accepted for treatment with coumarin derivatives.”
BackgroundSelf-citation
- Authors
- Sibbing, D., Steinhubl, S. R., Schulz, S., Schömig, A., & Kastrati, A.
- Corresponding author
- Sibbing, Dirk
- Venue
- Journal of the American College of Cardiology
- Publisher
- Elsevier BV
- Published
- 2010-07
- Volume
- 56
- Issue
- 4
- Pages
- 317-318
- ISSN
- 0735-1097 (ISSN-L)
- OpenAlex
- W81845835
- Cited by
- 208
- References
- 0
- Citations by year
- 2026: 2 · 2025: 5 · 2024: 2 · 2023: 6 · 2022: 2 · 2021: 6 · 2020: 3 · 2019: 12 · 2018: 7 · 2017: 10 · 2016: 15 · 2015: 23 · 2014: 20 · 2013: 33 · 2012: 32
- FWCI
- 20.63
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Journal of the American College of Cardiology (publishedVersion)
- PubMed (publishedVersion)
- mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich) (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Health Sciences › Medicine › Surgery › Coronary Interventions and Diagnostics
- Health Sciences › Medicine › Hematology › Platelet Disorders and Treatments
- Keywords
- platelet aggregation, clopidogrel, stent thrombosis, hemorrhage, clopidogrel resistance, interindividual variability, antiplatelet therapy, percutaneous coronary intervention
- MeSH terms
- Clopidogrel, Coronary Thrombosis, Hemorrhage, Humans, Platelet Aggregation, Ticlopidine, Time Factors, Receptors, Purinergic P2, Drug-Eluting Stents, Purinergic P2 Receptor Antagonists, Receptors, Purinergic P2Y12
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
